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Available online 30 November 2016Early-life stress adversely affects the development of the brain, and alters a variety of behaviors such as pain in
later life. In present study, we investigated how early-life stress (maternal separation or MS) can affect the noci-
ceptive response later in life. We particularly focused on the role of oxytocin (OT) in regulating nociception in
previously exposed (MS during early postnatal development) mice that were subjected to acute stress (restraint
stress or RS). Further, we evaluated whether such modulation of pain sensation in MS mice are regulated by
shared mechanisms of the OTergic and opioidergic systems. To do this, we assessed the underlying systems me-
diating the nociceptive response by administrating different antagonists (for both opioid and OTergic systems)
under the different experimental conditions (control vs MS, and control plus RS vs MS plus RS). Our results
showed that MS increased pain sensitivity in both tail-ﬂick and hot-plate tests while after administration of OT
(1 μg/μl/mouse, i.c.v) pain threshold was increased. Atosiban, an OT antagonist (10 μg/μl/mouse, i.c.v) abolished
the effects of OT.While acute RS increased thepain threshold in control (andnotMS)mice, treatingMSmicewith
OT normalized the pain response to RS. This latter effect was reversed by atosiban and/or naltrexone, an opioid
antagonist (0.5 μg/μl/mouse, i.c.v) suggesting that OT enhances the effect of endogenous opioids. OTergic system
is involved inmediating the nociception under acute stress inmice subjected to early-life stress and OTergic and
opioidergic systems interact to modulate pain sensitivity in MS mice.
© 2016 Elsevier Ltd. All rights reserved.Keywords:
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Social environment plays a critical role in shaping the brain
and behavior during lifespan (Lupien et al., 2009). Emerging lines
of evidence indicates that experiencing early-life stressful events
negatively affects the development of neural transmission system
such as circuits, which are involved in response to painful stimuliearch Center, Tehran University
Department of Pharmacology,
s, P.O. Box: 13145-784, Tehran,
oei, S Amiri.(Jennings et al., 2014; Uhelski and Fuchs, 2010; Amini-Khoei et al.,
2015). Neonatal maternal separation (MS), as an animal model of
early-life stress, has been shown to induce signiﬁcant changes in an-
imal behaviors such as abnormal response to stress as well as painful
stimuli (Kwok et al., 2014; Bernardi et al., 1986). In this regard, it has
been well-evident that early-life stressors (including MS) alter the
development of opioid system, which ideally regulates behaviors
such as nociception. Decrease in pain threshold and the activity of
the opioid system have been reported to play a role in the effects
of early-life stress on nociception (Amini-Khoei et al., 2015; Ploj
et al., 2003; Taylor et al., 2015).
On the other hand, endogenous hormone/neurotransmitter oxyto-
cin (OT) is potently involved in the regulation of several physiological
functions (Goodin et al., 2015). Environmental factors affect the
78 H. Amini-Khoei et al. / Neuropeptides 61 (2017) 77–85development of OT system through altering oxytocin levels and respon-
siveness. Clinical and preclinical evidence suggests that early-life
stressors, mainly those associated with poor maternal care, have long-
lasting effects on development of OT system (Buisman-Pijlman et al.,
2014). In case of animal studies, MS stress is able to induce signiﬁcant
alterations in the OTergic system activity by reducing the level of OT
and number of oxytocin-positive neurons in central nervous system
(CNS) (Veenema, 2012; Oreland et al., 2010; Lukas et al., 2010). OTergic
and opioidergic systems have several biological interactions, which reg-
ulate a variety of behaviors such as addictive behaviors, reward, attach-
ment and nociception (Carter, 2014; Russo et al., 2012; Georgiou et al.,
2016). In this regard, previous studies demonstrated that OT not only
induces a reduction in nociception, but enhances the antinociceptive
effects of morphine (Arletti et al., 1993). Further, OT null mice showed
reduced stress-induced antinociception suggesting that OT plays a role
in mediating the pain responses in response to stress (Robinson et al.,
2002).
Under acute stressful conditions, such as restraint stress (RS) in ro-
dents, activation of opioid and non-opioid pathways in the CNS is able
to suppress the pain (Robinson et al., 2002; Hohmann et al., 2005;
Madden et al., 1977). In addition, OT is known to mediate the analgesic
effects of acute restraint stress inmice, and endogenous opioids contrib-
ute to release of OT in the brain and periphery (Kwok et al., 2014; Han et
al., 2014; Condés-Lara et al., 2009; Ge et al., 2002). We recently showed
that MS stress changed mice nociceptive responses to acute RS, and
changes in opioid responsewere associatedwith altered seizure suscep-
tibility in animals (Amini-Khoei et al., 2015). Since both opioid and
OTergic system contribute to regulation of nociceptive behaviors, and
also both of them are negatively affected by early life stress, in this
study, we aimed to investigate; 1) role of OTergic system in mediating
the nociception under acute stress in mice subjected to early-life stress
and, 2) whether OTergic and opioidergic systems have possible interac-
tions in modulation of pain in MS mice.Fig. 1. Effects of MS and RS on nociceptive responses in the hot-plate and tail- ﬂick tests. Data p
was used for hot-plate threshold (A) andAUC forMPE% (B) analysis. Two-way ANOVA followed
and ***P b 0.001 compared with control group, $P b 0.05 and $$$P b 0.001 compared to control2. Materials and methods
2.1. Animals and housing conditions:
Pregnant (gestation day 1) NMRI mice were purchased from the
Pasteur Institute of Iran (Tehran, Iran), and housed individually under
standard laboratory conditions (temperature: 22 ± 2 °C, humidity:
50 ± 10%, 12-h light–dark cycle, and free access to food and water), in
the animal facility center of the Department of Pharmacology, School
of Medicine, Tehran University of Medical Sciences. Neonatal MS para-
digm was carried out based on previous studies (Amini-Khoei et al.,
2015; Desbonnet et al., 2010; Amiri et al., 2016). Brieﬂy, the day of
birth was considered as postnatal day (PND) 0 and pups were subse-
quently subjected to MS paradigm. Then, litters were brieﬂy handled
and separated from their mothers for 180 min daily during PND 2 to
PND 14, beginning at 09:00 a.m. At the PND 21, male offspring's were
housed in groups (4 mice per cage) until the PND 60. All procedures
in this study were carried out in accordancewith the National Institutes
of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH
publication # 80-23). Institutional guidelines were strictly followed for
animal care and use (Department of Pharmacology, School of Medicine,
Tehran University of Medical Sciences).
2.2. Study design
This study was consisted of 2 different experiments. In experiment 1
we aimed to investigate the role of OTergic and opioidergic systems and
their interaction in modulation of nociception in control and MSmice in
adulthood. To do this, we ﬁrstly applied OT at different doses (0.5, 0.75, 1
and 1.25 μg/μl/mouse) to treated both control andMSmice to determine
the effective and subthreshold doses of oxytocin in animals. On the next
step, bothMS and control micewere subjected to tail-ﬂick and hot-plate
tests. Eachmouse only used for one test. The treatment as primary factorresented as mean± S.E.M. (n=6–8). One-way ANOVA followed by Tukey's post-hoc test
by repeatedmeasurewas used for analysis ofMPE% of tail-ﬂick test (C). *P b 0.05, **P b 0.01
+ RS group, ##P b 0.01 compared to MS group.
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lows 1) saline, 2) OT (1 μg/μl/mouse, 15 min before test), 3) atosiban, a
speciﬁc antagonist of OT receptor, (10 μg/μl/mouse, 10 min before
test), and 4) atosiban + OT (atosiban 10 min prior to oxytocin injection
and 25 prior test).
In the experiment 2, we used RS, as an acute stress-induced
antinociception, to evaluate the involvement of OTergic and opioidergic
systems in mediating the nociception under acute stress in mice sub-
jected to early-life stress. To do this, both control andMSmicewere ran-
domly divided into following experimental groups; 1) RS (30 min prior
test), 2) RS + OT (1 μg/μl/mouse, immediately before RS and 30 min
prior test), 3) RS + naltrexone (an opioid antagonist, 0.5 μg/μl/mouse,
15 min before RS and 45 min prior test), 4) RS + atosiban (10 μg/μl/
mouse, 10 min before RS and 40 min prior trial), 5) RS + atosiban and
OT (atosiban 10 min prior to oxytocin injection and 40 min before ex-
amination), and 6) RS + naltrexone and OT (naltrexone 15 min before
oxytocin and 45 prior test) (Amini-Khoei et al., 2015; Robinson et al.,
2002). We used 30 min RS instead pharmacological manipulations
such as injection of morphine in order to evaluate the opioidergic
system. In this regards, it has been shown that applying 30 min RS to
rodents enhanced the level of endogenous opioids (Amini-Khoei et al.,
2015; Parikh et al., 2011). Considering, RS was used to enhance the
level of opioids and naltrexone was used to antagonize this effect.
All behavioral tests were carried out in adulthood (PND 60-62) in
both MS and control mice. Aforementioned drugs were injected
intracerebroventricularly (i.c.v) based on the method previously de-
scribed by Haley and McCormick (Haley and McCormick, 1957). Doses
and time of drug administrations were chosen according to previous
studies as well as our pilot studies (Han et al., 2014; Qi et al., 2012).
The sample size was calculated by power calculations using G powerFig. 2. Effects of different doses of oxytocin (0.5, 0.75, 1 and 1.25 μg/μl/mouse) on the nocicepti
S.E.M. (n=6–8). One-way ANOVA followed by Tukey's post-hoc testwas used for hot-plate thre
was used for analysis of MPE% of tail-ﬂick test (C). *P b 0.05 compared to saline treated group.software (ver.3.1.7, Franz Faul, Universitat Kiel, Germany). We set α
error at 0.05 and power (1-β) at 0.8 and the required total sample size
per group was calculated as 6–8 in behavioral tests. We also calculated
the power value in each experimental group and analyses have shown
that the power values were larger than 0.8 in all ANOVA analyses.
2.3. Evaluation of nociception
In order to investigate the involvement of OTergic and opioidergic
systems in the regulation of the effects of different forms of stress on no-
ciceptive response, hot-plate and tail-ﬂick testswere used. Hot plate and
tail ﬂick tests are validate models for assessment of pain. The difference
between these two tests is that hot plate test show the supraspinally
response while tail-ﬂick test assess the nociceptive response predomi-
nantly in the spinal level (Bannon and Malmberg, 2007; Langerman
et al., 1995). For the hot-plate test, mice were placed on a 52 ± 0.2 °C
heated plate (Socrel Hot-plate Model DS37; Ugo Basile, Comerio VA,
Italy) and the time last to lick the forepaw, hind paw or jump were
measured (Aloe et al., 2000). We considered cut- off time of 60 s to
avoid any tissue injury.
Tail-ﬂick test was done according to the criteria described by
D'amour and Smith (1941). Radiant heat was applied to the tail
(5–8 cm from the tip) using a tail-ﬂick apparatus (type 812, Hugo
Sachs Electronics, Germany). Tail-ﬂick latency was measured as the
time interval between the application of a standardized beam focused
on the tail and the abrupt removal of the tail from the nociceptive stim-
ulus. Multiple measures collected from the same animals at different
time points (mice re-tested every 15 min). The cut-off time of 10 s was
employed to prevent damage to the tail. Antinociception was measured
using the percent maximal possible effect (%MPE) according criteriave behavior of control mice in the hot-plate and tail- ﬂick tests. Data expressed as mean±
shold (A) and AUC forMPE% (B) analysis. Two-wayANOVA followed by repeatedmeasure
OT: oxytocin.
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baseline) / (10− baseline)] × 100. The area under the time response
curve (AUC) for each mouse was calculated by the trapezoidal method.
It should be considered that we used different groups of animals for
study of nociceptive effects of drugs in the tail-ﬂick and hot plate tests
and each mouse only used for one test.
2.4. Restraint stress procedure
In order to assess the function of the opioidergic system, acute stress
(30 min RS) was applied to both experimental groups. It has been
known that applying 30-min RS to rodents induced a strong analgesic
effect through enhancement of the endogenous opioid system (Parikh
et al., 2011; Drolet et al., 2001; Gamaro et al., 1998). Restraint stress par-
adigmwasperformed according to themethod described by Bonneau et
al. (1993). 50 ml falcon tubes with suitable ventilation holes (0.4 cm in
diameter) were used. Adult micewere restrained for 30min in the tube
without giving any food andwater. The controlmicewere also deprived
from food at the same time, however they remained in cages for that
speciﬁc time.
2.5. Statistical analysis
Comparison between groups was analyzed using one-way ANOVA
and two-way ANOVA followed by Tukey's post hoc test. Tail-ﬂick data
were analyzed using two-way ANOVA with repeated measures. In
two-way ANOVA analyses, row factor (RF) was considered as time
interval and column factor (CF) was deﬁned as treatments. P ˂ 0.05
was considered statistically signiﬁcant.Fig. 3. Effects of different doses of oxytocin (0.5, 0.75, 1 and 1.25 μg/μl/mouse) on the nociceptiv
(n=6–8). One-way ANOVA followed by Tukey's post-hoc test was used for hot-plate threshold
used for analysis of MPE% of tail-ﬂick test (C). #P b 0.05, ##P b 0.01 and ###P b 0.001 compared3. Results
3.1. Effects of MS and RS on pain threshold in the hot-plate and tail-ﬂick
tests
In the hot-plate test, two-way ANOVA revealed that there are signif-
icant differences among groups (Fint (9, 22) = 7.84, P b 0.05; FRF
(3, 22) = 11.28, P b 0.001; FCF (3, 22) = 12.36, P b 0.001, Fig. 1A).
Tukey's post-test analysis revealed that applying RS (30 min before
the test) to control mice signiﬁcantly enhanced hot-plate latency
compared with non-stressed controls (P b 0.001). However, applying
RS to MS mice, did not change the hot-plate latency when compared
to non-stressed MS animals (P N 0.05). Additionally, control + RS
mice showed an increase in the hot-plate threshold when compared
with MS + RS mice (P b 0.001).
Two-way ANOVA analysis for MPE% of tail-ﬂick test showed that
there are signiﬁcant differences in pain threshold among experimental
groups (Fint (9, 80) = 1.831, P b 0.05; FRF (3, 80) = 1.619, P b 0.05; FCF
(3, 80)=12.81, P b 0.001, Fig. 1B). Repeatedmeasure evaluation reveals
that RS (30min before test) signiﬁcantly enhancedMPE%of the tail-ﬂick
latency in control mice in comparison with saline-treated mice
(P b 0.05). Comparison between underwent RS groups demonstrated
that pain threshold in control + RS mice is more than MS + RS mice
(P b 0.01).
One-way analysis for the AUC of MPE% showed that there are signif-
icant differences among different sets of animals (Fint (9, 22) = 9.28,
P b 0.05; FRF (3, 22) = 18.15, P b 0.001; FCF (3, 22) = 10.42, P b 0.001,
Fig. 1C). Tukey's analysis demonstrated that applying RS in control
mice signiﬁcantly increased pain threshold when compared withe behavior ofMSmice in the hot-plate and tail-ﬂick tests Data expressed asmean± S.E.M.
(A) and AUC for MPE% (B) analysis. Two-way ANOVA followed by repeatedmeasure was
to saline-treated group. OT: oxytocin.
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decreased AUC of MS mice when compared with non-stressed MS
mice (P b 0.01). Moreover, RS signiﬁcantly decreased the AUC of
MPE% of MS mice in comparison with stress control mice (P b 0.001).
3.2. Various doses of OTwere injected in order to ﬁnd optimumdose on pain
threshold
In the hot-plate test, one-way ANOVA analysis showed that treat-
ment with different doses of oxytocin produced signiﬁcant changes in
the pain response in control (F (4, 32) = 11.11, P b 0.01, Fig. 2A) and
MS mice (F (4, 30) = 29.71, P b 0.001, Fig. 3A) when compared to
their saline-treated counterparts. Tukey's analysis showed that only ad-
ministration of OT (1.25 but not 0.5, 0.75 and 1 μg/μl/mouse) to control
mice signiﬁcantly increased pain threshold in comparison with saline-
treated control (P b 0.05). In MS mice, administration of OT (1 and
1.25 but not 0.5 and 0.75 μg/μl/mouse) increased pain threshold in com-
parison with saline-treated group (P b 0.001).
Two-way ANOVA analysis for MPE% of tail-ﬂick test demonstrated
that there are no signiﬁcant differences following administration of var-
ious doses of OT among control mice (Fint (12, 76)= 0.5103, P N 0.5; FRF
(3, 76) = 0.6829, P N 0.05; and FCF (4, 76) = 3.259, P b 0.05, Fig. 2B). In
contrast, same treatments in MS mice produced signiﬁcant changes in
MPE% (Fint (12, 80) = 2.199, P b 0.05; FRF (3, 80) = 10.18, P b 0.001;
FCF (4, 80) = 14.58, P b 0.001, Fig. 3B). Post-hoc analysis for control
mice showed that different doses of OT failed to increase pain threshold
in comparison with saline-treated group (P N 0.05). Results indicated
that treatment with OT (1 and 1.25 but not 0.5 and 0.75 μg/μl/mouse)
increased MPE% of MS mice when compared to saline-treated counter-
part (P b 0.05).Fig. 4. Effect of oxytocin (1 μg/μl/mouse) on the pain threshold of control mice in the hot-plate a
by Tukey's post-hoc test was used for hot-plate threshold (A) and AUC for MPE% (B) analysis. T
test (C). OT: oxytocin, ATO: atosiban.One-way ANOVA analysis for AUC ofMPE% showed that there are no
signiﬁcant differences among control mice treated with OT (F (4, 25)=
4.322, P N 0.05, Fig. 2C). Our ﬁnding showed that there are signiﬁcant
differences between MS mice following OT treatment in different
doses (F (4, 26) = 8.466, P b 0.001, Fig. 3C). Post-hoc test showed that
OT (all doses) did not increase pain threshold in comparison with sa-
line-treated group in control animals (P N 0.05). In contrast, OT (1 and
1.25 but not 0.5 and 0.75 μg/μl/mouse) signiﬁcantly decreased pain sen-
sitivity in MS mice when compared to saline-treated group (P b 0.05).
3.3. Oxytocin possessed analgesic effect inMSmice in the hot-plate and tail-
ﬂick tests
One-way ANOVA analysis for hot-plate test showed that either
oxytocin or atosiban failed to produce signiﬁcant alteration in latencies
of control mice (F (3, 27) = 2.250, P N 0.05, Fig. 4A). In contrast, same
treatments signiﬁcantly changed hot-plate latencies in MS mice (F (3,
26) = 23.21, P b 0.001, Fig. 5A). Tukey's analysis showed that there
are no signiﬁcant differences among treatment groups in comparison
to saline-treated mice (P N 0.05). Our results showed that OT (1 μg/μl/
mouse) signiﬁcantly increases pain threshold of MS mice when com-
pared to saline-treated counterparts (P b 0.001). Moreover, pretreat-
ment with atosiban signiﬁcantly reversed the effect of OT in MS mice
(P b 0.001).
Two-wayANOVA analysis for theMPE% of tail-ﬂick test revealed that
aforementioned treatments produced signiﬁcant alteration in MPE% of
MS mice (Fint (9, 84) = 2.759, P b 0.05; FRF (3, 80) = 1.212, P N 0.05;
FCF (3, 84) = 16.48, P b 0.001, Fig. 5B), but not in control mice (Fint (9,
80) = 0.4452, P N 0.05; FRF (3, 80) = 0.2122, P N 0.05; FCF (3, 80) =
1.282, P N 0.05, Fig. 4B). Repeated measure analysis showed that unlikend tail- ﬂick tests. Data presented asmean± S.E.M. (n=6–8). One-way ANOVA followed
wo-way ANOVA followed by repeated measure was used for analysis of MPE% of tail-ﬂick
Fig. 5. Effect of oxytocin (1 μg/μl/mouse) on nociceptive behavior ofMSmice in the hot-plate and tail-ﬂick tests. Data presented asmean± S.E.M. (n=6–8). One-wayANOVA followed by
Tukey's post-hoc test was used for hot-plate threshold (A) and AUC for MPE% (B) analysis. Two-way ANOVA followed by repeatedmeasure was used for analysis of MPE% of tail-ﬂick test
(C). #P b 0.05, ##P b 0.01 and ###P b 0.001 compared to saline treated group. &P b 0.05 and &&&P b 0.001 compared to OT group. OT: oxytocin, ATO: atosiban.
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increased MPE% of the tail-ﬂick in MS mice in comparison with saline-
treated counterparts (P b 0.01). Pretreatment with atosiban effectively
reversed the analgesic effect of OT in MS mice (P b 0.01).
One-way ANOVA analysis for the AUC of MPE% in the tail-ﬂick test
showed that unlike the control mice (F (3, 27) = 0.4456, P N 0.05,
Fig. 4C), treatment with OT, atosiban and OT+ atosiban signiﬁcantly
changed the AUC value of MS mice (F (3, 26) = 3.064, P b 0.05,
Fig. 5C). Tukey's pst-test analysis revealed that administration of OT
signiﬁcantly increased the AUC of MPE% of MS mice when compared
with MS saline-treated group (P b 0.05). Moreover, pretreatment with
atosiban signiﬁcantly decreased the analgesic effect of OT in AUC of
MPE% of MS mice (P b 0.05).
3.4. Analgesic effect of OT is partially modulated via opioid system
One-way ANOVA for hot-plate test revealed that OTergic and
opioidergicmanipulations signiﬁcantly altered pain threshold in control
(F (5, 36) = 31.61, P b 0.001, Fig. 6A) as well as MS (F (5, 38) = 58.19,
P b 0.001, Fig. 7A)mice. Tukey's post-hoc analysis demonstrated that OT
signiﬁcantly increased hot-plate threshold in control + RS (P b 0.05)
andMS+RS (P b 0.001)micewhen compared to their control counter-
parts. Further, unlike MS, injection of atosiban signiﬁcantly reduced the
pain threshold in control + RS mice in comparison with saline-treated
group (P b 0.05). Furthermore, co-administration of atosiban and nal-
trexone with OT as well as naltrexone alone in both stressed MS and
control mice signiﬁcantly decreased the pain threshold in comparison
with saline-treated counterparts (P b 0.01). In addition, pretreatment
with atosiban and naltrexone signiﬁcantly reversed the analgesic effect
of OT in both stressed MS and control mice (P b 0.001 for all).Two-way ANOVA analysis for the MPE% of tail-ﬂick revealed that
there are signiﬁcant differences among experimental groups following
OTergic and opioidergic interventions in control (Fint (15, 119) =
1.542, P b 0.05; FRF (3, 119) = 0.3140, P N 0.05; FCF (5, 119) = 4.820,
P b 0.001, Fig. 6B) and MS mice (Fint (15, 124) = 1.930, P b 0.05; FRF
(3, 124) = 1.351; P b 0.05, FCF (5, 124) = 5.815, P b 0.001, Fig. 7B).
Post-hoc analysis showed that MPE% following OT treatment signiﬁ-
cantly increased in comparison with RS + control group (P b 0.01),
which signiﬁcantly reversed with co-administration of naltrexone
and/or atosiban (P b 0.01, for both).
One-way ANOVA analysis for the AUC of MPE% in the tail-ﬂick test
showed that OTergic aswell as opioidergic interventions produce signif-
icant differences among animal sets in control (F (5, 36) = 17.22,
P b 0.001, Fig. 6C) and MS (F (5, 38) = 27.13, P b 0.001, Fig. 7C). Post-
hoc test analysis showed that the administration of OT in both control
(P b 0.05) and MS (P b 0.01) mice increased AUC value of tail-ﬂick in
comparison with RS counterparts. Tukey's analysis revealed that co-ad-
ministration of atosiban as well as naltrexone signiﬁcantly reversed the
effect of OT in AUC of stressed mice in both control and MS animals
(P b 0.01 and P b 0.001, respectively).
4. Discussion
The results of the current study showed that MS stress is able to
reduce the pain threshold in adult male mice. Further, results showed
that icv administration of OT increased the pain threshold in MS mice
and this effect was blocked by administration of atosiban suggesting
the involvement of OTergic system in abnormal nociception in MS
mice. Further, our results demonstrated that acute RS increased the
pain threshold in control (and not MS) mice suggesting that early
Fig. 6. Interaction of oxytocinergic and opioidergic on the nociceptive behavior of control mice in the hot-plate and tail ﬂick tests. Data presented as mean ± S.E.M. (n= 6–8). One-way
ANOVA followed by Tukey's post-hoc test was used for hot-plate threshold (A) and AUC for MPE% (B) analysis. Two-way ANOVA followed by repeated measure was used for analysis of
MPE% of tail-ﬂick test (C). *P b 0.05, and ⁎⁎P b 0.01 compared to saline treated group, @@P b 0.01 and @@@P b 0.001 compared to oxytocin treated group. OT: oxytocin, ATO: atosiban, NTX:
naltrexone, RS: restraint stress.
83H. Amini-Khoei et al. / Neuropeptides 61 (2017) 77–85life stress is able to alter nociceptive behaviors under acute stress
conditions. Finally, administration of OT to MS mice normalized the
pain responses to the RS. These effects were blocked by administration
of OT and opioid antagonists suggesting the involvement of OTergic and
opioidergic system in the regulation of pain responses to acute stress
following MS.
It is now well-known that experiencing early-life stress has a pro-
found and long-lasting effect on the development of the brain and be-
havior in later life (Lupien et al., 2009). Our results revealed that MS
signiﬁcantly altered the pain responses in animals. Applying 30 min of
RS to rodents has been reported to have analgesic effects by increasing
the levels of endogenous opioids (Amini-Khoei et al., 2015; Parikh et
al., 2011). In our study,MSmicedid not exhibit increasedpain threshold
following RS. This result is in agreement with previous studies that MS
disrupts the pain response under acute stress conditions (Amini-Khoei
et al., 2015; Kwok et al., 2014). In addition, early-life stress has been
shown to disrupt the development of opioid system and alter the anal-
gesic response to morphine treatment by reducing the number opioid
receptors (Kwok et al., 2014; Bernardi et al., 1986; Weaver et al.,
2007; Kalinichev et al., 2001). On the other hand, RS stress in known
to produce strong antinociception effects by increasing the opioid
tone. Thus, MS mice did not exhibit increased pain threshold following
RS because it seems that MS and RS neutralize effects of each other. It
is well-established that opioids have a pivotal role in CNS development
(Fleming et al., 1999). Endogenous opioid system and opioid receptors
are extensively expressed in various areas of the CNS (Erbs et al.,2014). Experiencing stressful conditions leads to induction of signiﬁcant
changes in the opioid system, which contributes to the regulation
of several behaviors like nociception and addiction (Sinha, 2008;
Martenson et al., 2009). In this regard, evidence indicates that
experiencing MS induces long-lasting alterations in the endogenous
opioid system such as reduction in the number of opioid receptors in
the brain (Kwok et al., 2014; Bernardi et al., 1986; Preter and Klein,
2014; Troisi et al., 2012). Previous investigations reported thatMS stress
decreased the pain threshold in rodents, and this effect was due to
hypo-function of the opioid system in the CNS, and MS mice were
more susceptible to the pain stimuli in comparison with control mice
(Bernardi et al., 1986; Kehoe and Blass, 1986). In line with these ﬁnd-
ings, we recently reported that abnormal nociceptive behaviors in MS
mice are associated with impairment in opioid system (Amini-Khoei
et al., 2015).
Interestingly, unlike control mice, the administration of subthresh-
old dose of OT (1 μg/μl/mouse) increased the pain threshold in MS
mice, while pretreatment with atosiban signiﬁcantly decreased the an-
algesic effect of OT. These results suggest that MS-induced decrease in
pain threshold may be associated with reduced activity of OTergic sys-
tem. In this regard, previous research has shown that MS is able to de-
crease the levels of OT and oxytocin-positive neurons in different
regions of the brain (Veenema, 2012; Oreland et al., 2010; Lukas et al.,
2010). Also, development and functioning of the OT system is sensitive
towards peripheral stimuli such as social environment and stress
(Buisman-Pijlman et al., 2014). Development of endogenous OT system
Fig. 7. Interaction of oxytocinergic and opioidergic on the nociceptive behavior ofMSmice in the hot-plate and tailﬂick tests. Data presented asmean±S.E.M. (n=6–8). One-way ANOVA
followed by Tukey's post-hoc test was used for hot-plate threshold (A) and AUC for MPE% (B) analysis. Two-way ANOVA followed by repeated measure was used for analysis of MPE% of
tail-ﬂick test (C). #P b 0.05, ##P b 0.01 and ###P b 0.001 compared to saline treated group, &P b 0.05, &&P b 0.01 and &&&P b 0.001 compared to oxytocin treated group. OT: oxytocin, ATO:
atosiban, NTX: naltrexone, RS: restraint stress.
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2012). A recent study by Lukas et al. showed that the density of OT
receptors changes during the lifespan and is profoundly inﬂuenced by
MS (Lukas et al., 2010). Also, it has been demonstrated that maternal
care (grooming) positively affects the expression of OT receptors in
the brain (Champagne, 2008). Thus, it is possible that abnormal noci-
ceptive behavior in MS mice is related to the abnormal OTergic system
activity. Also, our results indicate that OT plays an important role inme-
diating the nociceptive behaviors under acute stress conditions. Preclin-
ical and clinical evidence demonstrated that OT has analgesic properties
(Condés-Lara et al., 2009; Li et al., 2015; Juif and Poisbeau, 2013; Rash et
al., 2014). In this regard, previous studies showed that direct adminis-
tration of OT into the brain, spinal cord or systematically possessed
analgesic effects (Gao and Yu, 2004; Miranda-Cardenas et al., 2006;
Reeta et al., 2006). Moreover, it has been shown that atosiban signiﬁ-
cantly attenuated the analgesic effects of oxytocin (Li et al., 2015). In
this work, we also observed that treating animals with naltrexone
abolished the effects of OT suggesting the interaction between opioid
and OTergic system in mediating the nociception under acute stress
conditions. It has been reported that OTergic system activity is closely
related to the opioidergic system. Also, it has been shown that opioids
are linked with central oxytocin-related analgesic effects (Fleming et
al., 1999; Reeta et al., 2006). Animal studies revealed that icv adminis-
tration of OT has strong analgesic effect, which signiﬁcantly reversed
by icv injection of opioid antagonists (Ge et al., 2002; Reeta et al.,
2006). Therefore, our ﬁndings suggest that abnormal interaction
between OTergisc and opioidergic systems at least partly underlies thealtered responses of MS male mice to analgesic effects of acute RS. We
also investigated the effects of MS on nociceptive responses of female
mice. We found that abnormal responses to painful stimuli in adult fe-
male mice were associated with hormonal level and status of the estrus
cycle of animals (data not shown). This study has certain limitations.
This study showed that OT (and to some extent opiodergic system) is
involved in abnormal nociceptive alterations following MS, and in
response to acute stress. However, we did not show which brain struc-
tures are involved and furthermolecular assessments should be done in
order tomeasure the alterations of OT or opioid system activity afterMS
or RS in the animals.
5. Conclusion
In conclusion, the results of the current study showed that 1) MS in-
duced abnormal nociceptive responses in the form of thermos-sensa-
tion in the adult male mice, 2) both opioidergic and OTergic systems
are involved in altered nociception 3) OTergic and opioidergic systems
mediate the analgesic effects of RS, and 4) MS disrupts the analgesic re-
sponse of the RS at least partly through decreasing the OTergic system
activity in the CNS.
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